BHCM
JAZZ icon

Boulder Hill Capital Management’s Jazz Pharmaceuticals JAZZ Stock Holding History

Boulder Hill Capital Management’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-8,800
Closed -$1.37M – 164
2022
Q2 		$1.37M Buy
+8,800
New +$1.35M 1.57% 9

Other funds holding JAZZ

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
PCM
Polaris Capital Management Boston, Massachusetts $1.06B AUM 40.82% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Boulder Hill Capital Management's JAZZ Position: Q3 2022 in Review

Boulder Hill Capital Management sold out of Jazz Pharmaceuticals (JAZZ) in Q3 2022, closing a stake of 8,800 shares — an estimated $1.37M sold.

Boulder Hill Capital Management first reported a position in JAZZ in Q2 2022 and held it in 1 quarter. The position peaked at $1.37M in Q2 2022. 468 funds tracked by Wall St. Rank hold JAZZ as of Q3 2022.

  • Boulder Hill Capital Management reported no remaining Jazz Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
  • Boulder Hill Capital Management sold 8,800 Jazz Pharmaceuticals shares in Q3 2022, an estimated $1.37M.
  • Boulder Hill Capital Management first reported a position in Jazz Pharmaceuticals in Q2 2022 and held it in 1 quarter.
  • Boulder Hill Capital Management's Jazz Pharmaceuticals position peaked at $1.37M in Q2 2022.
  • 468 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q3 2022.

Based on Boulder Hill Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.